Alfa Financial posts uptick in profit as it unveils special dividend March 14, 2024 Asset finance software company Alfa Financial Software Holdings has posted an uptick in annual profits while announcing a special dividend as part of plans to return £9.7m to shareholders.
Shell chief nets £8m as firm moves goalposts on net zero strategy March 14, 2024 Wael Sawan's pay packet totals nearly the same as that received by his BP counterpart
GCP Asset Backed Income proposes shuttering trust March 14, 2024 The debt-focused trust's merger with GCP Infrastructure fell through in September after a "significant minority" of the trust's shareholders said they did not support it, leading to a strategic review.
Sales rise fails to stop Build-a-Bear Workshop entering the red March 14, 2024 The UK arm of Build-a-Bear Workshop fell to a loss despite increasing its sales in its stores by 35 per cent, newly-filed accounts have revealed.
EU AI Act: What does it mean for UK business post-Brexit? March 14, 2024 The EU AI Act, aimed at controlling AI systems on a risk-based approach, gained an overwhelming majority in favour, with 523 votes.
Bridgepoint reports ‘robust’ investment returns despite tough market conditions March 14, 2024 Private equity firm Bridgepoint has posted an 11.5 per cent rise in underlying pretax profit despite "more challenging, but improving, market conditions".
Trainline shares soar as ticket sales hit £5.3bn on ‘less severe’ rail strike impact March 14, 2024 Trainline shares soared over ten per cent this morning as ticket sales reached £5.3bn, reflecting British rails ongoing post-pandemic recovery.
Record pay day for Timpson family as group ‘far exceeds expectations’ March 14, 2024 The Timpson family paid themselves the largest dividend in the group's recent history after its financial performance "far exceeded our expectations".
Vistry launches buyback as revenue boosted by affordable housing push March 14, 2024 Vistry has reported a rise in revenue during the full year as its transition to affordable housing appears to be paying off.
Astrazeneca: Pharma giant snaps up rare disease biotech firm Amoylt March 14, 2024 The acquisition, which is meant to "bolster" Astrazenca's rare disease arm Alexion, brings with it a Phase III investigational therapeutic peptide meant for hypoparathyroidism